Doramectin

In the field of parasitic disease prevention and control, macrolide antiparasitic drugs have long occupied the core clinical position due to their broad-spectrum activity. Doramectin, as a new generation of avermectin derivative under this category, enhances the permeability of parasite nerve cell membranes to chloride ions, inhibits nerve conduction and prompts the paralysis and death of parasites, and has the advantages of high efficiency, low residue and long duration of action. It is mainly used for the prevention and treatment of parasitic infections such as nematodes, ticks, mites and lice in and on livestock, and is one of the core drugs to ensure the health of livestock and poultry and improve the economic benefits of breeding in large-scale breeding, which also conforms to the policy orientation of reducing and limiting the use of antibiotics in China's breeding industry.

The global market size of veterinary antiparasitic API has exceeded 3.5 billion US dollars, with a compound annual growth rate of about 4.3%. Among them, due to its outstanding clinical advantages, the market growth rate of doramectin is higher than the average level of the category, with a compound annual growth rate of 6.8%. At present, the global production capacity is mainly concentrated in China and India. Domestic enterprises have occupied nearly 60% of the global supply share by virtue of the cost advantage of process optimization. With the improvement of the intensification degree of the global breeding industry, there is still room for continuous growth in its market demand. (The above data are publicly verifiable industry statistics.)

The original research enterprise of doramectin is Pfizer, and the original research brand name is "Dectomax". The expiration time of its core compound patent in the United States is 2006, and the core patent in the EU also expired in 2007. The main dosage forms approved by the original research are injection and pour-on solution, and common specifications include 10mg/ml injection and 5mg/ml pour-on solution. Relevant dosage forms have been included in the FDA Reference Listed Drug Catalog. For the domestic market, at present, the doramectin APIs of a number of enterprises have obtained CDE registration numbers (A status), and a number of domestic doramectin injections and pour-on solutions have been approved for marketing, which can fully meet the needs of the domestic breeding market. (The data is as of June 2025, please refer to the official website of CDE for the latest information.)

CATO can provide a full set of impurity reference standards for doramectin API. Most of the products support spot supply. For spot products, orders placed before 16:00 can be shipped on the same day. Relevant products also meet the compliance requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, and can provide stable and reliable reference standard support for pharmaceutical enterprises in API R&D, quality research and declaration work.